Literature DB >> 1303281

Identical point mutations of PMP-22 in Trembler-J mouse and Charcot-Marie-Tooth disease type 1A.

L J Valentijn1, F Baas, R A Wolterman, J E Hoogendijk, N H van den Bosch, I Zorn, A W Gabreëls-Festen, M de Visser, P A Bolhuis.   

Abstract

We have investigated the peripheral myelin protein gene, PMP-22, in a family with Charcot-Marie-Tooth disease type 1A (CMT1A). The DNA duplication commonly found in CMT1A was absent in this family, but strong linkage existed between the disease and the CMT1A marker VAW409R3 on chromosome 17p11.2. We found a point mutation in PMP-22 which was completely linked with the disease. The mutation, a proline for leucine substitution in the first putative transmembrane domain, is identical to that recently found in the Trembler-J mouse. The presence of this PMP-22 defect in this CMT1A family and the location of PMP-22 within the DNA duplication associated with CMT1A suggest that both structural alteration and overexpression of PMP-22 may lead to the disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1303281     DOI: 10.1038/ng1292-288

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  94 in total

1.  A new variant of Charcot-Marie-Tooth disease type 2 is probably the result of a mutation in the neurofilament-light gene.

Authors:  I V Mersiyanova; A V Perepelov; A V Polyakov; V F Sitnikov; E L Dadali; R B Oparin; A N Petrin; O V Evgrafov
Journal:  Am J Hum Genet       Date:  2000-06-07       Impact factor: 11.025

2.  Morphogenesis of the node of Ranvier: co-clusters of ankyrin and ankyrin-binding integral proteins define early developmental intermediates.

Authors:  S Lambert; J Q Davis; V Bennett
Journal:  J Neurosci       Date:  1997-09-15       Impact factor: 6.167

3.  Hereditary neuropathy with liability to pressure palsies: the same molecular defect can result in diverse clinical presentation.

Authors:  E Andreadou; C Yapijakis; G P Paraskevas; P Stavropoulos; C Karadimas; V P Zis; P Davaki; N Karandreas; M Rentzos; C Tsakanikas; D Vassilopoulos; C Papageorgiou
Journal:  J Neurol       Date:  1996-03       Impact factor: 4.849

4.  Therapeutic strategies for the inherited neuropathies.

Authors:  Michael E Shy
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

5.  Recombination hot spot in a 3.2-kb region of the Charcot-Marie-Tooth type 1A repeat sequences: new tools for molecular diagnosis of hereditary neuropathy with liability to pressure palsies and of Charcot-Marie-Tooth type 1A. French CMT Collaborative Research Group.

Authors:  J Lopes; E LeGuern; R Gouider; S Tardieu; N Abbas; N Birouk; M Gugenheim; P Bouche; Y Agid; A Brice
Journal:  Am J Hum Genet       Date:  1996-06       Impact factor: 11.025

6.  A new point mutation affecting the fourth transmembrane domain of PMP22 results in severe de novo Charcot-Marie-Tooth disease.

Authors:  R Navon; B Seifried; N S Gal-On; M Sadeh
Journal:  Hum Genet       Date:  1996-05       Impact factor: 4.132

7.  Identification of a duplication of Xq28 associated with bilateral periventricular nodular heterotopia.

Authors:  J M Fink; W B Dobyns; R Guerrini; B A Hirsch
Journal:  Am J Hum Genet       Date:  1997-08       Impact factor: 11.025

8.  Long-term analyses of innervation and neuromuscular integrity in the Trembler-J mouse model of Charcot-Marie-Tooth disease.

Authors:  Jessica Renee Nicks; Sooyeon Lee; Kathryne Ann Kostamo; Andrew Benford Harris; Amanda M Sookdeo; Lucia Notterpek
Journal:  J Neuropathol Exp Neurol       Date:  2013-10       Impact factor: 3.685

Review 9.  The PMP22 gene and its related diseases.

Authors:  Jun Li; Brett Parker; Colin Martyn; Chandramohan Natarajan; Jiasong Guo
Journal:  Mol Neurobiol       Date:  2012-12-07       Impact factor: 5.590

Review 10.  Evolution in health and medicine Sackler colloquium: Genomic disorders: a window into human gene and genome evolution.

Authors:  Claudia M B Carvalho; Feng Zhang; James R Lupski
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.